Abstract Details

Title Alterations of the gut microbiome in different stages of multiple sclerosis

Topic Multiple Sclerosis

Presentation(s) MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 122

Objective The aim of this study was to reveal the characteristics of the gut microbiome in different stages of multiple sclerosis (MS).

Background MS generally starts as relapsing remitting form (RRMS), but often shifts into secondary progressive MS (SPMS).

Design/Methods We analyzed gut microbiome of patients with RRMS (n=62), SPMS (n=15), atypical MS (n=21), neuromyelitis optica (n=20), and healthy controls (HC; n=55) by 16S-rRNA gene and whole metagenomic sequencing data and by fecal metabolites.

Results Each patient group had a number of species having significant changes in abundance compared with HC, including short chain fatty acid (SCFA)-producing bacteria reduced in RRMS. Changes in some species had close association with clinical severity of the patients. A marked reduction in butyrate and propionate biosynthesis and corresponding metabolic changes were confirmed in RRMS compared with HC (p=0.0007 and 0.003). Although limited differences between patient groups were shown by 16S-based microbial composition analysis, metagenome-based functional data disclosed an increase in microbial genes involved in DNA mismatch repair in SPMS as compared to RRMS. Together with an increased ratio of cysteine persulfide to cysteine (p=0.02) in SPMS revealed by sulfur metabolomics, we postulate that excessive DNA oxidation takes place in the gut of SPMS (Takewaki et al, PNAS. 2020).

Conclusions

Gut microbiome is differentially altered in the different stages of MS. In particular, reduced SCFA biosynthesis in RRMS and elevated oxidative level in SPMS were characteristic.

Authors/Disclosures
Daiki Takewaki PRESENTER	Daiki Takewaki has nothing to disclose.
Wakiro Sato	Wakiro Sato has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen. Wakiro Sato has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis Pharma. Wakiro Sato has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma.
Takashi Yamamura, MD (National Inst of Neuroscience)	Dr. Yamamura has nothing to disclose.

��ɫ��

��ɫ��